HomeProductsBioactive CompoundsNF-kB SignalingNF-??BRevaprazan
Chemical structure of CAS 199463-33-7

Revaprazan

In Stock•Starting at $68 for 5 mg
CAS No.199463-33-7
MDL No.N/A
MFC22H23FN4
MW362.40
InChI KeyLECZXZOBEZITCL-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mgTo Be Confirmed$68In Stock
25 mgTo Be Confirmed$238In Stock
100 mgTo Be Confirmed$897In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Revaprazan is an isoquinoline compound.

CAS No.199463-33-7
Product NameRevaprazan
Heavy Atom Count27Rotatable Bond Count3
Atom Stereo Count1Bond Stereo Count0
HBA4HBD1
TPSA41.050 ŲCharge0
Exact Mass362.19067Complexity968.55
pKa9.247XLogP5.100

Related Articles

Studies related to this compound and its mechanism of action

Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.

Journal of medicinal chemistry • Vol. 65, Issue 11 • 2022
PMID: 35604136DOI: 10.1021/acs.jmedchem.2c00338

Novel pyrimidines as acid pump antagonists (APAs).

Bioorganic & medicinal chemistry letters • Vol. 20, Issue 19 • 2010
PMID: 20810280DOI: 10.1016/j.bmcl.2010.08.007

Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.

Journal of gastroenterology and hepatology • Vol. 25, Issue 10 • 2010
PMID: 20880169DOI: 10.1111/j.1440-1746.2010.06408.x

N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.

The Journal of pharmacology and experimental therapeutics • Vol. 328, Issue 2 • 2009
PMID: 18981288DOI: 10.1124/jpet.108.146415

Documentation